8/17/2012 | PP | BioSante prices $3.48 million public sale of equity units at $1.4725
|
7/6/2012 | CVLM | BioSante issues stock for $2.47 million of 3.125% convertible notes
|
2/16/2012 | CVLM | BioSante exchanges common stock for $4 million of 3.125% convertibles
|
2/8/2012 | CVLM | BioSante to issue stock in exchange for $5 million 3.125% convertibles
|
7/28/2011 | PP | BioSante Pharmaceuticals prices $48 million public stock sale at $3
|
7/27/2011 | PP | BioSante Pharmaceuticals to price public offering of its common stock
|
5/27/2011 | CVHYPF | BioSante files $150 million shelf for stock, preferreds, units
|
3/4/2011 | PP | BioSante arranges $25.15 million registered direct offering of units
|
3/4/2011 | PP | BioSante to raise $25.1 million in registered direct offering of units
|
12/30/2010 | PP | BioSante offers details on $18 million registered offering of units
|
12/29/2010 | PP | BioSante to pocket $18 million via registered direct units offering
|
12/23/2010 | PP | BioSante extends $25 million equity financing facility by one year
|
6/24/2010 | PP | Market Commentary: BioSante settles unit sale; Exiqon seeks DKK 19.7 million via placement; Aurcana to sell units
|
6/21/2010 | PP | Market Commentary: Chesapeake wraps $900 million placement; Olympus to sell gold loan notes; BioSante brings deal
|
6/21/2010 | PP | New Issue: BioSante prices $15 million registered direct offering of units
|
5/21/2010 | CVHYPF | BioSante Pharmaceuticals files $75 million shelf for stock, preferreds
|
3/5/2010 | PP | New Issue: BioSante details $18 million registered direct offering of equity units
|
3/4/2010 | PP | New Issue: BioSante clinches $18 million commitment in registered direct offering of units
|
10/14/2009 | CVSS | Cell Genesys, BioSante complete merger; BioSante assumes obligations for 3.125% convertibles
|
8/13/2009 | PP | New Issue: BioSante orchestrates $12 million registered direct offering of units
|
5/29/2009 | CVHY | BioSante files $75 million shelf registration for stock, preferreds
|
12/16/2008 | PP | Market Commentary: Maple Leaf wraps C$70 million; Commonwealth sells stock; OncoMethylome plans deal
|
12/16/2008 | PP | New Issue: BioSante arranges $25 million committed equity financing facility
|
6/15/2007 | PP | Market Commentary: Arena Resources secures $100.45 million; Payment Data Systems gets equity line
|
6/14/2007 | PP | New Issue: BioSante completes stock placement for $18.33 million
|
6/14/2007 | PP | Market Commentary: Lancashire plans $48.93 million offering; BioSante seals $18.3 million PIPE
|
5/25/2007 | PP | Market Commentary: Hardy Oil and Gas announces £21 million placement; Dynamite plans C$40 million deal
|
5/25/2007 | PP | New Issue: BioSante plans $16.53 million private placement of stock
|
11/14/2006 | BT | BioSante ends quarter with $10.3 million, will continue to burn $650,000 per month until year end
|
9/29/2006 | BT | Market Commentary: Exelixis follow-on set for Oct. 2 week; ImaRx on tap; Biomira bounces; Labopharm, Pharmacopeia lower
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
7/11/2006 | PP | Market Commentary: Signet Energy changes hands following C$18.73 million PIPE; Med-Emerg closes $3.5 million stock sale
|
7/10/2006 | PP | Market Commentary: The Knot walks down aisle with $50.18 million PIPE; Protalex pockets $15.17 million from stock sale
|
7/10/2006 | BTPP | New Issue: BioSante Pharmaceuticals gets $7.63 million from sale of stock
|
7/10/2006 | BT | Market Commentary: Connetics drops 33% on lowered forecast; Antigenics off 5%; Depomed off; Acadia gains
|
5/12/2006 | BT | BioSante's net loss for the quarter up to $3.2 million
|
5/8/2006 | BT | BioSante releases positive data on vaccine enhancer CaP
|
4/24/2006 | BT | BioSante study suggests BioVant may enhance effectiveness of bird-flu vaccine
|
4/21/2006 | BT | Antares licensee BioSante submits NDA for transdermal estrogen product
|
4/19/2006 | BT | BioSante Pharmaceuticals files NDA for Bio-E-Gel
|
3/31/2006 | BT | BioSante Pharmaceuticals says net loss shrinks to $0.50 per share in 2005
|
3/22/2006 | BT | BioSante says needle-free delivery of anthrax vaccine effective
|
3/10/2006 | BT | BioSante's Bio-E-Gel reduces hot flashes at lowest dose during phase 3 study
|
2/27/2006 | BT | BioSante, MATC form licensing agreement for CaP technology aesthetic medicine
|
2/16/2006 | BT | BioSante submits FDA application for Bio-E-Gel to treat menopausal hot flashes
|
10/6/2005 | BT | BioSante started by Rodman & Renshaw at market outperform
|
8/25/2005 | BT | BioSante CEO: Company in good financial condition with $12 million in bank, declining cash burn rate
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|